A Phase 4 interventional study of Atorvastatin in Dyslipidemias, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 20 sites in Korea, Republic of. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-03-12.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies testing atorvastatin in Dyslipidemias — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Dyslipidemias.
Among the 47 studies testing atorvastatin in Dyslipidemias, this one is the 11th largest by enrollment, is one of 4 that started in 2007, is one of 22 in phase 4, and was the 11th registered.
1,250 studies on the registry are indexed under Dyslipidemias; 178 are open to participants now.
Browse Dyslipidemias studies →1 of the 47 studies testing atorvastatin in Dyslipidemias is open now, in 1 country. Recruiting first, the newest first:
Yonsei University · Sites in Korea, Republic of
Ages 19–80
By country, each count listing its studies:
Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 4 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 425 is above the median of 100 across 987 interventional studies indexed under Dyslipidemias.
Median enrollment 165 across the 47 interventional studies. Of the 42 that completed or were terminated, 11 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 47 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
15 studies in Dyslipidemias by Viatris Inc.: none open now, none under way, none of them phase 3. Of 15 finished, 4 (27%) have results posted.
Among the 15 studies in Dyslipidemias by Viatris Inc., this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2007, is one of 11 in phase 4, and was the 7th registered.
Viatris Inc.’s Dyslipidemias studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 47 studies testing atorvastatin in Dyslipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 15 in Dyslipidemias:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the percentage of Korean dyslipidemic subjects in the total group and each cardiovascular risk group achieving LDL-C target as defined by NCEP ATP Ⅲ criteria at starting doses of 10mg, 20mg and 40mg of atorvastatin after 8 weeks of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
this patient group consists of dyslipidemia patients with various CVD risk factors
Drug: Atorvastatin
Prescription of 10/20/40mg dose atorvastatin based on the personal risk factor that is defined in the NCEP ATP III guideline in a single patient group
Percent of Subjects in the Total and Each Cardiovascular Risk Group Achieving Low Density Lipoprotein-cholesterol (LDL-C) Target After 8 Weeks of Treatment.
LDL-C Responders by visit and by risk group - full analysis set (FAS)
Time frame: Week 8
Percent of Subjects in the Total Group and Each Cardiovascular Risk Group Achieving LDL-C Target After 4 Weeks of Treatment.
LDL-C Responders by visit and by risk group - FAS
Time frame: Week 4
Changes in Lipid Parameters in Subjects in the Total Group and Each Cardiovascular Risk Group After 4 and 8 Weeks of Treatment
Mean baseline, change and percent change from baseline in lipid parameters by risk group - FAS. HDL-C: high density lipoprotein-cholesterol; TC: total cholesterol; TG: triglyceride
Time frame: Weeks 4 and 8
Percent Changes From Baseline in Lipid Parameters in Subjects in the Total Group and Each Cardiovascular Risk Group After 4 and 8 Weeks of Treatment
Mean percent changes from baseline in lipid parameters by risk group - FAS. HDL-C: high density lipoprotein-cholesterol; TC: total cholesterol; TG: triglyceride
Time frame: weeks 4 and 8
Subjects Who Achieved LDL-C Target With no Titration of Atorvastatin and After One Step Titration of Atorvastatin.
LDL-C responders at week 8 by titration status and risk groups - FAS, efficacy evaluation (EVAL), and FAS (no last observation carried forward, LOCF)
Time frame: 8 weeks
Percent of Subjects Who Achieved LDL-C Target With no Titration of Atorvastatin and After One Step Titration of Atorvastatin.
LDL-C responders at week 8 by titration status and risk groups - FAS, efficay evaluation (EVAL), and FAS (no last observation carried forward, LOCF)
Time frame: 8 weeks
Change From Baseline in High Sensitive Circulating C-reactive Protein (Hs-CRP) After 4 and 8 Weeks of Treatment
Median baseline, and change from baseline in hs-CRP by risk group - FAS
Time frame: 4 and 8 weeks
Percent Change From Baseline in High Sensitive Circulating C-reactive Protein (Hs-CRP) After 4 and 8 Weeks of Treatment
Percent change from baseline in hs-CRP by risk group - FAS
Time frame: 4 and 8 weeks
Changes From Baseline in Selected Inflammatory Markers After 8 Weeks of Treatment.
Median baseline, and change from baseline in monocyte chemoattractant protein (MCP-1), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) by risk group - FAS
Time frame: Baseline, and 8 weeks
Percent Changes From Baseline in Selected Inflammatory Markers After 8 Weeks of Treatment.
Percent changes from baseline in monocyte chemoattractant protein (MCP-1), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) by risk group - FAS
Time frame: 8 weeks
Study was conducted at 20 centers in Korea
| Milestone | Total Treatment Group (All Subjects Who Received Atorvastatin) |
|---|---|
| Started | 425 |
| Completed | 390 |
| Not completed | 35 |
| Withdrew: Adverse event related to study drug | 10 |
| Withdrew: Adverse event not related to study drug | 7 |
| Withdrew: Withdrawal by subject | 6 |
| Withdrew: Protocol violation, & subject schedule | 12 |
LDL-C Responders by visit and by risk group - FAS
| Percent subjects achieved LDL-C target | Total | Low Risk | Medium Risk | High Risk |
|---|---|---|---|---|
| Percent of Subjects in the Total Group and Each Cardiovascular Risk Group Achieving LDL-C Target After 4 Weeks of Treatment. | 81.9 (77.9 to 85.5) | 85.7 (67.3 to 96.0) | 95.5 (84.5 to 99.4) | 79.9 (75.2 to 84.0) |
Mean baseline, change and percent change from baseline in lipid parameters by risk group - FAS. HDL-C: high density lipoprotein-cholesterol; TC: total cholesterol; TG: triglyceride
| mg/dL (ratio for Scalar) | Total | Low Risk | Medium Risk | High Risk |
|---|---|---|---|---|
| LDL-C baseline | 151.7 (149.1 to 154.4) | 187.0 (179.8 to 194.1) | 160.6 (154.3 to 167.0) | 147.7 (144.9 to 150.5) |
| LDL-C (week 4) | -63.5 (-66.2 to -60.8) | -73.8 (-82.7 to -64.8) | -65.1 (-73.5 to -56.7) | -62.4 (-65.4 to -59.4) |
| LDL-C (week 8) | -65.3 (-68.0 to -62.5) | -77.6 (-88.3 to -66.9) | -64.2 (-72.4 to -56.0) | -64.4 (-67.4 to -61.4) |
| HDL-C baseline | 48.3 (47.3 to 49.3) | 50.5 (47.4 to 53.7) | 48.0 (45.5 to 50.5) | 48.2 (47.0 to 49.3) |
| HDL-C (week 4) | 0.1 (-0.7 to 0.9) | -0.8 (-3.6 to 2.0) | 3.3 (0.9 to 5.7) | -0.2 (-1.1 to 0.7) |
| HDL-C (week 8) | 0.5 (-0.4 to 1.3) | 2.1 (-1.6 to 5.9) | 3.0 (0.9 to 5.1) | 0.0 (-1.0 to 1.0) |
| Non-HDL-C baseline | 175.5 (172.5 to 178.5) | 209.9 (201.0 to 218.8) | 187.1 (179.9 to 194.4) | 171.1 (167.9 to 174.4) |
| Non-HDL-C (week 4) | -69.4 (-72.3 to -66.5) | -75.4 (-87.8 to -63.1) | -71.3 (-80.2 to -62.5) | -68.6 (-71.8 to -65.4) |
| Non-HDL-C (week 8) | -70.7 (-73.7 to -67.7) | -80.9 (-93.9 to -67.8) | -72.1 (-80.3 to -64.0) | -69.7 (-73.0 to -66.4) |
| LDL-C/HDL-C ratio baseline | 3.2 (3.1 to 3.3) | 3.7 (3.4 to 4.0) | 3.4 (3.2 to 3.6) | 3.2 (3.1 to 3.3) |
| LDL-C/HDL-C Ratio (Scalar) week 4 | -1.4 (-1.4 to -1.3) | -1.4 (-1.7 to -1.1) | -1.5 (-1.7 to -1.3) | -1.3 (-1.4 to -1.3) |
| LDL-C/HDL-C Ratio (Scalar) week 8 | -1.4 (-1.5 to -1.3) | -1.6 (-1.9 to -1.2) | -1.5 (-1.7 to -1.3) | -1.4 (-1.5 to -1.3) |
| TC baseline | 223.9 (220.8 to 227.0) | 262.3 (253.9 to 270.8) | 235.1 (228.0 to 242.3) | 219.3 (216.0 to 222.6) |
| TC (week 4) | -69.4 (-72.4 to -66.4) | -78.2 (-89.3 to -67.1) | -68.0 (-77.2 to -58.8) | -68.8 (-72.2 to -65.5) |
| TC (week 8) | -70.4 (-73.4 to -67.3) | -80.7 (-94.2 to -67.3) | -69.1 (-77.2 to -61.1) | -69.7 (-73.1 to -66.2) |
| TG baseline | 154.1 (146.2 to 162.1) | 150.7 (128.6 to 172.8) | 152.3 (130.3 to 174.2) | 154.7 (145.6 to 163.7) |
| TG (week 4) | -29.1 (-35.5 to -22.7) | -11.5 (-43.0 to 20.0) | -16.6 (-31.4 to -1.8) | -32.1 (-39.2 to -25.1) |
| TG (week 8) | -29.3 (-37.9 to -20.7) | -20.9 (-51.3 to 9.5) | -18.5 (-36.3 to -0.7) | -31.4 (-41.3 to -21.5) |
Mean percent changes from baseline in lipid parameters by risk group - FAS. HDL-C: high density lipoprotein-cholesterol; TC: total cholesterol; TG: triglyceride
| Percent | Total | Low Risk | Medium Risk | High Risk |
|---|---|---|---|---|
| LDL-C % change from baseline (week 4) | -40.9 (-42.3 to -39.5) | -39.5 (-44.1 to -35.0) | -39.6 (-43.8 to -35.5) | -41.2 (-42.8 to -39.6) |
| LDL-C % change from baseline (week 8) | -42.0 (-43.4 to -40.7) | -41.2 (-46.6 to -35.8) | -39.3 (-43.5 to -35.1) | -42.5 (-44.0 to -41.0) |
| HDL-C % change from baseline (week 4) | 1.7 (0.0 to 3.4) | -0.2 (-6.0 to 5.6) | 7.7 (2.3 to 13.1) | 1.1 (-0.8 to 2.9) |
| HDL-C % change from baseline (week 8) | 2.6 (0.8 to 4.4) | 5.6 (-2.1 to 13.2) | 6.7 (2.3 to 11.1) | 1.8 (-0.2 to 3.9) |
| Non-HDL-C % change from baseline (week 4) | -38.7 (-40.1 to -37.4) | -35.5 (-40.9 to -30.1) | -37.7 (-41.5 to -33.8) | -39.1 (-40.6 to -37.7) |
| Non-HDL-C % change from baseline (week 8) | -39.4 (-40.7 to -38.1) | -38.2 (-44.1 to -32.2) | -38.3 (-42.1 to -34.5) | -39.7 (-41.1 to -38.2) |
| LDL-C/HDL-C ratio % change from baseline (week 4) | -41.3 (-43.0 to -39.7) | -36.7 (-44.3 to -29.0) | -44.1 (-48.9 to -39.3) | -41.4 (-43.2 to -39.6) |
| LDL-C/HDL-C ratio % change from baseline (week 8) | -42.6 (-44.3 to -40.9) | -41.6 (-49.5 to -33.7) | -42.9 (-48.0 to -37.7) | -42.6 (-44.5 to -40.8) |
| TC % change from baseline (week 4) | -30.3 (-31.4 to -29.2) | -29.7 (-33.6 to -25.7) | -28.5 (-31.9 to -25.2) | -30.6 (-31.9 to -29.3) |
| TC % change from baseline (week 8) | -30.7 (-31.9 to -29.6) | -30.4 (-35.2 to -25.5) | -29.2 (-32.3 to -26.2) | -31.0 (-32.2 to -29.7) |
| TG % change from baseline (week 4) | -8.2 (-12.9 to -3.6) | 4.4 (-18.5 to 27.3) | -8.3 (-17.7 to 1.2) | -9.3 (-14.4 to -4.1) |
| TG % change from baseline (week 8) | -9.8 (-14.9 to -4.8) | -6.3 (-27.0 to 14.5) | -7.0 (-20.4 to 6.4) | -10.5 (-16.2 to -4.8) |
LDL-C responders at week 8 by titration status and risk groups - FAS, efficacy evaluation (EVAL), and FAS (no last observation carried forward, LOCF)
| Participants | Total | Low Risk | Medium Risk | High Risk |
|---|---|---|---|---|
| FAS population responders no titration | 339 | 24 | 41 | 274 |
| FAS population responders 1-step titration | 56 | 3 | 1 | 52 |
| EVAL population responders no titration | 305 | 22 | 39 | 244 |
| EVAL population responders 1-step titration | 53 | 3 | 1 | 49 |
| FAS population (no LOCF) no titration | 336 | 24 | 41 | 271 |
| FAS population (no LOCF) 1-step titration | 56 | 3 | 1 | 52 |
LDL-C responders at week 8 by titration status and risk groups - FAS, efficay evaluation (EVAL), and FAS (no last observation carried forward, LOCF)
| percentage of participants | Total | Low Risk | Medium Risk | High Risk |
|---|---|---|---|---|
| FAS population, no titration | 89.1 (85.3 to 92.2) | 95.8 (78.9 to 99.9) | 97.6 (87.1 to 99.9) | 87.2 (82.7 to 90.9) |
| FAS population, 1-step titration | 82.1 (69.6 to 91.1) | 100.0 (29.2 to 100.0) | 100.0 (2.5 to 100.0) | 80.8 (67.5 to 90.4) |
| EVAL population, no titration | 91.1 (87.4 to 94.1) | 95.5 (77.2 to 99.9) | 97.4 (86.5 to 99.9) | 89.8 (85.2 to 93.3) |
| EVAL population, 1-step titration | 83.0 (70.2 to 91.9) | 100.0 (29.2 to 100.0) | 100.0 (2.5 to 100.0) | 81.6 (68.0 to 91.2) |
| FAS population (no LOCF), no titration | 89.0 (85.1 to 92.1) | 95.8 (78.9 to 99.9) | 97.6 (87.1 to 99.9) | 87.1 (82.5 to 90.8) |
| FAS population (no LOCF), 1-step titration | 82.1 (69.6 to 91.1) | 100.0 (29.2 to 100.0) | 100.0 (2.5 to 100.0) | 80.8 (67.5 to 90.4) |
Median baseline, and change from baseline in hs-CRP by risk group - FAS
| mg/dL | Total | Low Risk | Medium Risk | High Risk |
|---|---|---|---|---|
| Baseline | 0.108 (0.094 to 0.126) | 0.082 (0.060 to 0.112) | 0.075 (0.059 to 0.126) | 0.122 (0.102 to 0.137) |
| Median change from baseline (week 4) | -0.008 (-0.014 to -0.005) | -0.008 (-0.028 to -0.001) | -0.002 (-0.014 to 0.023) | -0.010 (-0.018 to -0.005) |
| Median change from baseline (week 8) | -0.015 (-0.021 to -0.009) | -0.011 (-0.034 to 0.018) | -0.001 (-0.021 to 0.010) | -0.018 (-0.027 to -0.010) |
LDL-C Responders by visit and by risk group - full analysis set (FAS)
| Percentage of participants | Total | Low Risk | Medium Risk | High Risk |
|---|---|---|---|---|
| Percent of Subjects in the Total and Each Cardiovascular Risk Group Achieving Low Density Lipoprotein-cholesterol (LDL-C) Target After 8 Weeks of Treatment. | 86.0 (82.3 to 89.2) | 92.9 (76.5 to 99.1) | 95.5 (84.5 to 99.4) | 84.3 (80.0 to 87.9) |
Percent change from baseline in hs-CRP by risk group - FAS
| percentage | Total | Low Risk | Medium Risk | High Risk |
|---|---|---|---|---|
| Median % change from baseline (week 4) | -12.346 (-21.429 to -4.651) | -13.941 (-35.055 to -1.923) | -2.553 (-22.951 to 25.926) | -16.197 (-24.182 to -4.523) |
| Median % change from baseline (week 8) | -18.605 (-24.138 to -11.111) | -18.621 (-37.363 to 20.690) | -1.472 (-26.364 to 14.925) | -20.561 (-25.333 to -12.346) |
Median baseline, and change from baseline in monocyte chemoattractant protein (MCP-1), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) by risk group - FAS
| pg/dL | Total | Low Risk | Medium Risk | High Risk |
|---|---|---|---|---|
| MCP-1 baseline | 302.7 (295.0 to 311.7) | 305.2 (267.9 to 340.6) | 317.7 (294.2 to 386.4) | 301.6 (291.7 to 310.0) |
| MCP-1 change from baseline (week 8) | 39.8 (21.3 to 66.7) | -15.0 (-61.4 to 45.9) | -22.4 (-102.9 to 42.6) | 59.4 (33.6 to 74.9) |
| IL-6 baseline | 0.40 (0.40 to 0.50) | 0.30 (0.10 to 0.60) | 0.40 (0.30 to 0.80) | 0.50 (0.40 to 0.60) |
| IL-6 change from baseline (week 8) | 0.00 (0.00 to 0.00) | 0.00 (-0.30 to 0.00) | -0.10 (-0.30 to 0.00) | 0.00 (0.00 to 0.00) |
| TNF-alpha baseline | 0.10 (0.10 to 0.10) | 0.10 (0.10 to 0.30) | 0.20 (0.10 to 0.30) | 0.10 (0.10 to 0.10) |
| TNF-alpha change from baseline (week 8) | 0.00 (0.00 to 0.00) | 0.00 (-0.10 to 0.00) | 0.00 (-0.10 to 0.00) | 0.00 (0.00 to 0.00) |
Percent changes from baseline in monocyte chemoattractant protein (MCP-1), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) by risk group - FAS
| percent | Total | Low Risk | Medium Risk | High Risk |
|---|---|---|---|---|
| MCP-1 % change (week 8) | 14.0 (7.8 to 22.3) | -5.6 (-18.6 to 18.7) | -8.0 (-34.2 to 21.4) | 18.2 (11.1 to 24.7) |
| IL-6 % change (week 8) | 0.00 (0.00 to 0.00) | 0.00 (-50.00 to 0.00) | -12.50 (-45.45 to 25.00) | 0.00 (0.00 to 0.00) |
| TNF-alpha % change (week 8) | 0.00 (0.00 to 0.00) | 0.00 (-50.00 to 0.00) | 0.00 (-42.86 to 0.00) | 0.00 (0.00 to 0.00) |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Total Treatment Group (All Subjects Who Received Atorvastatin) | — | — | — |
| Event | Total Treatment Group (All Subjects Who Received Atorvastatin) |
|---|---|
| Cerabral infarctionNervous system disorders | 2/425 |
| Wrist fractureInjury, poisoning and procedural complications | 1/425 |
| Event | Total Treatment Group (All Subjects Who Received Atorvastatin) |
|---|---|
| NasopharyngitisInfections and infestations | 8/425 |
| HeadacheNervous system disorders | 6/425 |
| Age, Continuous(Years) | Total Treatment Group (All Subjects Who Received Atorvastatin) |
|---|---|
| Females between 18 and 80 years | 62.9 ± 8.6 |
| Males between 18 and 80 years | 58.6 ± 10.2 |
| Sex: Female, Male(Participants) | Total Treatment Group (All Subjects Who Received Atorvastatin) |
|---|---|
| Female | 195 |
| Male | 230 |
The record gives a start of Oct 2007, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atorvastatin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →